15.50
0.00 (0.00%)
| Previous Close | 15.50 |
| Open | 15.50 |
| Avg. Volume (3M) | 3,199,667 |
| Market Cap | 1,820,087,040 |
| Price / Earnings (Forward) | 29.24 |
| Price / Sales | 5.79 |
| Price / Book | 3.30 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -20.39% |
| Operating Margin (TTM) | -31.40% |
| Diluted EPS (TTM) | -0.500 |
| Quarterly Revenue Growth (YOY) | 34.20% |
| Quarterly Earnings Growth (YOY) | 3,119.20% |
| Total Debt/Equity (MRQ) | 54.64% |
| Current Ratio (MRQ) | 11.93 |
| Operating Cash Flow (TTM) | 63.55 M |
| Levered Free Cash Flow (TTM) | 33.54 M |
| Return on Assets (TTM) | -0.07% |
| Return on Equity (TTM) | -10.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Dynavax Technologies Corporatio | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | -1.00 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 0.58% |
| % Held by Institutions | 108.60% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |